Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue 1, 2015, Pages

  Cecchini, Michael ^a   Sznol, Mario ^a   Seropian, Stuart ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Allogeneic transplant; CTLA 4 antigen; Graft vs host disease; Immunotherapy; Interleukin 2; Ipilimumab; Melanoma; Programmed cell death 1 receptor and immune related adverse events

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CELECOXIB; CHOP REGIMEN; CYCLOSPORIN; INTERLEUKIN 2; IPILIMUMAB; METHOTREXATE; PACLITAXEL; PEMBROLIZUMAB; STEROID; TACROLIMUS; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ANGIOSARCOMA; ARTICLE; BONE MARROW BIOPSY; BRAIN METASTASIS; CANCER STAGING; CASE REPORT; CHILL; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; ERYTHEMA; FATIGUE; GAMMA KNIFE RADIOSURGERY; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; HUMAN TISSUE; HYPOTENSION; IMMUNOTHERAPY; LYMPHADENOPATHY; MALE; MENTAL DISEASE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; PANCYTOPENIA; PRIORITY JOURNAL; RASH; SPLENOMEGALY; VITILIGO;

EID: 84977126608     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-015-0054-4     Document Type: Article

References (10)

1. Curtis RE, et al. Solid Cancers after Bone Marrow Transplantation. N Engl J Med 1997, 336(13):897-904. 10.1056/NEJM199703273361301, 9070469.
2. Kaufman H, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013, 10(10):588-598. 10.1038/nrclinonc.2013.153, 23982524.
3. Blazar BR, et al. Opposing Roles of CD28:B7 and CTLA-4:B7 Pathways in Regulating In Vivo Alloresponses in Murine Recipients of MHC Disparate T Cells. J Immunol 1999, 162(11):6368-6377. 10352249.
4. Blazar BR, et al. Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN- -Dependent Mechanism. J Immunol 2003, 171(3):1272-1277. 10.4049/jimmunol.171.3.1272, 12874215.
5. Bashey A, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009, 113(7):1581-1588. 10.1182/blood-2008-07-168468, 18974373.
6. Zhou J, et al. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant 2011, 17(5):682-692. 10.1016/j.bbmt.2010.08.005, 20713164.
7. Saranga-Perry V, et al. Recent developments in the medical and surgical treatment of melanoma. CA Cancer J Clin 2014, 64(3):171-185. 10.3322/caac.21224, 24676837.
8. Hodi FS, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 2010, 363(8):711-723. 10.1056/NEJMoa1003466, 20525992.
9. Pavletic SZ, Fowler DH. Are we making progress in GVHD prophylaxis and treatment?. ASH Education Program Book 2012, 2012(1):251-264.
10. Flowers, M.E.D., Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria, ed. M.E.D. Flowers, et al. Vol. 117. 2011. 3214-3219..